Author

Prateek Khanna

Dana-Farber Cancer InstituteORCID 0000-0002-7577-0101Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 4 Assay:bulk RNA-seq· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1

Frequent Co-Authors

Jiao LiiD· 4 shared Ananthan SadagopaniD· 3 shared Prathyusha KondaiD· 3 shared Srinivas Raghavan ViswanathaniD· 3 shared Toni K. ChoueiriiD· 3 shared Bingchen LiiD· 2 shared Mingkee AchomiD· 2 shared Qingru XuiD· 2 shared

Activity by Year

2025-2026 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Jiao LiORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Detection and monitoring of translocation renal cell carcinoma via plasma cell-free epigenomic profiling

Simon Garinet, Karl Semaan, Jiao Li, Ananthan Sadagopan, John Canniff, Noa Phillips, Kelly S. Klega, Medha Panday, Hunter Savignano, Matthew P. Davidsohn, Kevin Lyons, Alessandro Medda, Prateek Khanna, Mingkee Achom, Prathyusha Konda, , Srinivas Raghavan Viswanathan

This paper detects and monitors translocation renal cell carcinoma (tRCC) using plasma cell-free epigenomic profiling, achieving high accuracy in distinguishing tRCC from other cancers and healthy controls.

Journal of Clinical Investigation · Feb 1, 2026Peer-reviewedGenomics

Phenotypic screening converges on CDK9 inhibition as a therapeutic strategy in translocation renal cell carcinoma

Dharma R. Thapa, Riva Deodhar, Adam P. Skepner, Prathyusha Konda, Meng Zhou, Joseph P. Bluck, C. Pichlo, Yantong Cui, Paige Stocker, Prateek Khanna, Jiao Li, Jonathan M. Tsai, Alison Leed, Sandy Gould, Maria Alimova, , Srinivas Raghavan Viswanathan

The paper identifies CDK9 inhibition as a therapeutic strategy for translocation renal cell carcinoma through phenotypic screening and mechanistic analysis.

bioRxiv · Aug 25, 2025 · PreprintCancer Biology

Dual Inhibition of CDK4/6 and mTORC1 Establishes a Preclinical Strategy for Translocation Renal Cell Carcinoma

Shikha Gupta, Prateek Khanna, Eddy Saad, Renée Maria Saliby, Shatha AbuHammad, Jiao Li, Bingchen Li, Prathyusha Konda, Usman Ali Ahmed, Ananthan Sadagopan, Qingru Xu, Ziad Bakouny, Wenxin Vincent Xu, Ramaprasad Srinivasan, Toni K. Choueiri, Srinivas R. Viswanathan

This study identifies CDK4/6 and mTORC1 pathway activation in tRCC and shows that their dual inhibition synergistically suppresses tRCC cell growth in vitro and xenografts in vivo.

bioRxiv · Jul 11, 2025 · PreprintCancer Biology

TFE3 fusions direct an oncogenic transcriptional program that drives OXPHOS and unveils vulnerabilities in translocation renal cell carcinoma

Jiao Li, Kaimeng Huang, Meha Thakur, Fiona McBride, Ananthan Sadagopan, Daniel S Gallant, Prateek Khanna, Yasmin Nabil Laimon, Bingchen Li, Razan Assaad Mohanna, Maolin Ge, Cary N. Weiss, Mingkee Achom, Qingru Xu, Sayed Matar, , Srinivas Raghavan Viswanathan

This study identifies TFE3 fusions driving OXPHOS in tRCC and reveals EGLN1 inhibition as a therapeutic target.

Nature Metabolism · Feb 6, 2025Peer-reviewedCancer Biology